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Abstract
Background: MPG is a cell-permeable peptide with proven efficiency to deliver macromolecular
cargoes into cells. In this work, we examined the efficacy of MPG as an N-terminal tag in a fusion
protein to deliver a protein cargo and its mechanism of transduction.
Results: We examined transduction of MPG-EGFP fusion protein by live imaging, flow cytometry,
along with combination of cell biological and pharmacological methods. We show that MPG-EGFP
fusion proteins efficiently enter various mammalian cells within a few minutes and are co-localized
with FM4-64, a general marker of endosomes. The transduction of MPG-EGFP occurs rapidly and
is inhibited at a low temperature. The entry of MPG-EGFP is inhibited by amiloride, but cytochalasin
D and methyl-β-cyclodextrin did not inhibit the entry, suggesting that macropinocytosis is not
involved in the transduction. Overexpression of a mutant form of dynamin partially reduced the
transduction of MPG-EGFP. The partial blockade of MPG-EGFP transduction by a dynamin mutant
is abolished by the treatment of a m i l o r i d e .  M P G - E G F P  t r a n s d u c t i o n  i s  a l s o  o b s e r v e d  i n  t h e
mammalian oocytes.
Conclusion: The results show that the transduction of MPG fusion protein utilizes endocytic
pathway(s) which is amiloride-sensitive and partially dynamin-dependent. Collectively, the MPG
fusion protein could be further developed as a novel tool of "protein therapeutics", with potentials
to be used in various cell systems including mammalian oocytes.
Background
Cell-permeable or cell-penetrating peptides (CPPs) are
considered a promising method to deliver macromolecu-
lar cargoes into live cells across lipid bilayers. These pep-
tides commonly bear stretches of basic amino acids. Many
CPPs have been shown to deliver oligonucleotides or
siRNA efficiently across cell membrane with or without
covalent conjugation [1]. As for the delivery of proteins,
expression and purification of CPP-fusion protein in a
single step produces more stable form of cargo for in vitro
and in vivo uses. The Protein Transduction Domain
(PTD) from TAT protein of the human immunodeficiency
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virus (HIV), is known to deliver large proteins up to ~120
kDa into cells in the form of fusion protein [2,3]. Thus, it
has been in the forefront of protein delivery and is being
widely used to deliver various proteins for functional
experiments [4]. Other CPPs have been tested for their
efficiency for protein delivery by cross-linking, by simple
mixing, or as a fusion protein form [5-7].
While the list of applicable CPPs is expanding, recent
works have been focused on identifying the mechanisms
of cellular uptake of CPPs. These studies generally utilize
arrays of endocytosis inhibitors to identify specific endo-
cytic pathway involved in the uptake [8-11]. These works
provided evidence that the uptake of TAT PTD, pol-
yarginine, and other peptides is dependent on the lipid
rafts-mediated macropinocytosis, "the cell-drinking"
process.
MPG is a designed CPP comprised of two independent
domains [12]. The first 17 amino acids of the N-terminus
is derived from glycine-rich region of the viral gp41 [13]
and the hydrophilic C-terminus from nuclear localization
signal (NLS) of the SV40 large T antigen [14]. The original
MPG peptide is acetylated at the N-terminus and synthe-
sized with a cysteamide group at the C-terminus. This
form was used to deliver siRNA or oligonucleotide and the
effectiveness was proven in several cell systems [12,15]. A
recent report showed that the initial interaction of MPG
peptide with the cell surface uses negatively charged gly-
cosaminoglycans. Furthermore, the mechanism of MPG
peptide-mediated delivery of nucleic acids seems to
involve Rac1-dependent remodeling of actin network
within the cell [16]. However, the potential for MPG as a
carrier of protein cargoes has not been investigated.
The present investigation was initiated to identify CPPs
which can be effectively used for the protein delivery in
the form of CPP-fusion proteins. We chose 8 known CPP
sequences and prepared CPP-EGFP fusion proteins
[5,6,12,17-20]. Our initial screening unveiled the efficient
transduction of modified MPG-EGFP fusion proteins into
various cell lines and thus we focused on identifying the
mechanism of cellular uptake of MPG-EGFP. We report
herein that the uptake of MPG-fusion proteins utilizes
specific endocytic pathway which is sensitive to amiloride
and partially dependent on dynamins.
Results
High transduction efficiency of MPG-EGFP fusion protein 
in mammalian cells
We initially chose 8 CPPs that have not been used to
deliver protein cargoes in the form of fusion proteins
(Table 1), and prepared CPP-EGFP fusion proteins. These
CPPs, in peptide forms, had all been shown effective in
delivering oligonucleotides or nucleic acids into cells
when used as a mixture. As N-terminal tags of EGFP
recombinant proteins, however, most of these CPPs did
not seem to enter cells efficiently (data not shown).
Among the tested CPPs, MPG-EGFP entered the cells and
exhibited a punctate vesicular pattern of EGFP fluores-
cence (Figure 1A). Efficient transduction of MPG-EGFP
was confirmed in various cell lines, including AN3CA,
293T, NIH3T3, F9, BV2, and HT29. Treatment of MPG-
EGFP at 40, 80, or 120 μg/ml for more than 24 hr did not
cause any significant cytotoxicity (all above 93% survival
rate).
Representative figures are shown in Figure 1A. Intracellu-
lar localization of MGP-EGFP was mostly cytoplasmic
vesicular patterns reminiscent of endosomal vesicles.
Since the fixation of cells reportedly affects the subcellular
localization of CPPs [21], we compared the subcellular
localization of MPG-EGFP in live and fixed cells. As
shown in Figure 1A, no significant redistribution of MPG-
EGFP signal in the cells was noted. To examine if MPG-
EGFP proteins are present within endosomal vesicles, we
stained the MPG-EGFP-treated HeLa cells with a general
fluorescence marker of endocytosis FM4-64 [10]. As
shown in Figure 1B, most of the MPG-EGFP overlaps with
the endosomal staining of FM4-64 (red). Localization of
MPG-EGFP in intracellular vesicles was further confirmed
by the vesicle fractionation procedure. By using the differ-
ential centrifugation, the vesicle fractionation procedure
separates the particulate fractions containing most of the
subcellular vesicles from the cytosolic supernatant. As
shown in Figure 1C, the vesicle fraction of the MPG-EGFP
treated cells showed a clear immunoreactive EGFP, con-
firming the vesicular localization of MPG-EGFP. The
immunoreactive EGFP was detected in the cytosolic frac-
tion at a low intensity. The result shows that MPG-EGFP
proteins are mainly localized in endosomes. The confocal
live imaging clearly demonstrated that MPG-EGFP signals
are present within multiple endosomes. These vesicles
dynamically move around and a small number of them
fuses or disappears during several minutes of observation
(see Additional file 1).
In our work, two different MPG sequences were adapted
from published works [12] and are shown in Table 1 as
MPG1 and MPG2. These MPG sequences do not contain
the linker region and thus are modified from the original
sequence. The seventh amino acid is tryptophan in MPG1
and phenylalanine in MPG2. This modification of W to F
at the seventh position was reported to enhance nuclear
localization of the mixed cargo [22]. Both forms, without
significant difference, showed effective transduction and
exhibited similar cellular distribution and signal intensity
(data not shown). Therefore, we used MPG1-EGFP in all
the subsequent experiments (indicated as MPG-EGFP
thereafter).BMC Biotechnology 2009, 9:73 http://www.biomedcentral.com/1472-6750/9/73
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Rapid internalization of MPG-EGFP depends on 
endocytosis
Internalization of MPG-EGFP occurs within 1 min and the
signal gradually intensifies until about 30 min of incuba-
tion (Figure 2A). To eliminate the possibility that MPG-
EGFP adheres to the cell surface, we washed MPG-EGFP-
treated cells with the acid buffer for 30 sec before observ-
ing under a fluorescence microscope in all experiments.
The acid wash did not significantly reduce the fluores-
cence signals of MPG-EGFP, suggesting that the observed
signal is not an artifact produced by MPG-EGFP adhering
to the cell surface.
To address if the entry of MPG fusion protein depends on
endocytosis, we examined the entry of MPG-EGFP at 4°C
when general endocytosis is blocked. MPG-EGFP was
added to BV2 cells or HeLa cells at 40 μg/ml. BV2 cells
were co-treated with FM4-64. As shown in Figure 2B, the
uptake of MPG-EGFP was significantly reduced in both
cell lines at 4°C, showing only a weak surface binding in
some cells. FM4-64 staining was also absent at 4°C in BV2
cells, suggesting efficient blockade of endocytosis in our
experimental condition. This result suggests that an
energy-dependent endocytic pathway is responsible for
the transduction of MPG-EGFP. In the next series of exper-
iments, we investigated which pathway of endocytosis is
associated with the uptake of the MPG fusion protein.
Effects of endocytosis inhibitors on the entry of MPG-
EGFP
Endocytosis occurs in cells using multiple pathways, such
as clathrin-mediated, caveolae-mediated, lipid rafts-medi-
ated endocytosis, and macropinocytosis [23]. By using
various inhibitors of endocytosis, we determined which
endocytic pathway is associated with MPG-EGFP uptake.
Cytochalasin D, an inhibitor of actin polymerization,
blocks actin-dependent macropinocytosis. Amiloride is a
sodium channel blocker and is known to block macropi-
nocytosis [24]. Inhibitors were added to the cells 30 min
prior to the addition of MPG-EGFP and were maintained
at the same concentrations for the duration of the experi-
ments (Figure 3B). When cytochalasin D was added prior
to MPG-EGFP treatment, most of cells became round due
to the depolymerization of actin filaments but the distinct
vesicular pattern of MPG-EGFP remained unchanged. In
contrast, 4 mM amiloride treatment effectively reduced
MPG-EGFP uptake as shown in Figure 3A. Methyl-β-cyclo-
dextrin (MβCD) depletes cholesterol from the plasma
membrane, and is used as an inhibitor of the caveolae-
mediated endocytosis and macropinocytosis [25]. Both of
these pathways are known to be dependent on choles-
terol-rich lipid rafts. Surprisingly, MβCD treatment signif-
icantly increased the fluorescence intensity of MPG-EGFP
(Figure 3B). Collectively, these results show that the
uptake of MPG-EGFP seems to utilize amiloride-sensitive
endocytic pathway, but is not dependent on the organiza-
tion of actin filaments or cholesterol. These experiments
were repeated several times with similar results (Figure
3C).
MPG-EGFP uptake is independent of caveolins but partly 
dependent on the GTPase activity of dynamins
To examine if caveolin-mediated endocytosis is involved
in the transduction of MPG-EGFP, we used the human T
lymphocyte Jurkat cells which is known to lack caveolin-
1 [26]. EGFP or MPG-EGFP was added to the cells at 40
μg/ml for 1 hr and cells were processed for FACS analysis
after the acid wash. As shown in Figure 4A, the transduc-
tion efficiency of MPG-EGFP in Jurkat cells was above
60%. Although the overall efficiency of MPG-EGFP trans-
duction in Jurkat cells was not as high as in adherent cells,
the successful entry of MPG-EGFP shows that this trans-
duction was not dependent on the caveolin-mediated
endocytosis.
Dynamin GTPase is required for several types of endocy-
tosis including clathrin-mediated endocytosis [23]. Trans-
ferrin is a marker of dynamin-dependent endocytosis.
Thus, we first examined if transferrin is co-localized with
MPG-EGFP within cells. As shown in Figure 4B, the vesi-
cles containing MPG-EGFP partially overlapped with
those of transferrin-Alex Fluor 546, showing a yellow flu-
orescence. Amiloride treatment did not seem to affect the
endocytosis of transferrin but most of MPG-containing
vesicles disappeared by this treatment. Some vesicles with
both transferrin and MPG were noted.
Table 1: CPPs tested herein as EGFP fusion forms (reviewed in [1])
CPP Sequence Reference
Buforin 2 TRSSRAGLQFTPVGRVHRLLRK [17]
Transportan GWTLNSAGYLLGKINLKALAALAKKIL [5]
Transportan 10 AGYLLGKINLKALAALAKKIL [18]
MPG1 GALFLGWLGAAGSTMGAPKKKRKV [12]
MPG2 GALFLGFLGAAGSTMGAPKKKRKV [12]
KALA WEAKLAKALAKALAKHLAKALAKALKACEA [19]
Pep-1 KETWWETWWTEWSQPKKKRKV [6]
SynB1 RGGRLSYSRRRFSTSTGR [20]BMC Biotechnology 2009, 9:73 http://www.biomedcentral.com/1472-6750/9/73
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The observation suggests that dynamins may be partly
involved in the transduction of MPG-EGFP. Thus, we
tested this hypothesis by using the dominant-negative
form of dynamin-1, DynK44A. DynK44A, a dominant-nega-
tive form blocking the GTPase activity of dynamin I, has
been widely used to elucidate the involvement of these
proteins in endocytosis [10,27,28]. This form is capable of
blocking the GTPase activity of both dynamin-1 and
dynamin-2 [29]. Dynamin-1 is a neuron-specific form,
while dynamin-2 is ubiquitously expressed [30,31]. We
overexpressed DynK44A in HeLa cells and added 40 μg/ml
MPG-EGFP and 50 μg/ml transferrin (Figure 5A). Expres-
sion of DynK44A was detected by an antibody specific to
dynamin-1 [28]. As shown in Figure 5A, overexpression of
DynK44A in HeLa cells blocks the entry of transferrin effec-
tively. While MPG-EGFP entry is shown in DynK44A-
expressing HeLa cells, the number of vesicular structures
in these cells was notably reduced (arrowheads). Further-
more, amiloride treatment in DynK44A-expressing HeLa
cells almost completely abolished MGP-EGFP uptake,
Efficient transduction of the MPG-EGFP fusion protein into  various cell lines Figure 1
Efficient transduction of the MPG-EGFP fusion pro-
tein into various cell lines. A. 40 μg/ml MPG-EGFP was 
added to AN3CA or HeLa cells. NIH3T3, BV2, 293T, and 
HT29 were also tested (data not shown). MPG-EGFP exhib-
its a punctate vesicular pattern in the cytoplasm in cells. Fixa-
tion of the cells with 4% PFA (fixed) did not alter the 
subcellular distribution of MPG-EGFP. Cells were all 
observed under a confocal microscope. Fixed cells were 
counterstained with TO-PRO-3 iodide (shown in blue, 
1:500). B. MPG-EGFP is mostly present in the endosomes. 
Cells were stained with 5 μg/ml FM4-64, a general marker of 
endocytosis (shown in red), and visualized under a confocal 
microscope without fixation. Overlapping of MPG-EGFP sig-
nal and FM4-64 staining generates a yellow fluorescence. C. 
Vesicle fractionation was performed using HeLa cells treated 
with EGFP or MPG-EGFP for 1 hr. -, no treatment; EGFP, 40 
μg/ml EGFP; MPG-EGFP, 40 μg/ml MPG-EGFP; S, superna-
tant containing the cytosolic fraction; P, pellet containing the 
intracellular vesicles. Western blotting was performed with 
anti-GFP antibody.
Internalization of MPG-EGFP occurs rapidly and is inhibited  at 4°C Figure 2
Internalization of MPG-EGFP occurs rapidly and is 
inhibited at 4°C. A. EGFP or MPG-EGFP was added to 
HeLa cells at 40 μg/ml and cells were fixed with 4% PFA at 
indicated times after the acid wash. Fixed cells were visual-
ized under an inverted fluorescence microscope. B. 40 μg/ml 
MPG-EGFP was added to BV2 or HeLa cells in 2-well slide 
chambers for 30 min, with (BV2) or without (HeLa) 5 μg/ml 
FM4-64. To maintain 4°C, cells and all reagents were pre-
cooled for 20 min on ice. Cells were fixed with 4% PFA for 
20 min, mounted, and visualized under a confocal micro-
scope.BMC Biotechnology 2009, 9:73 http://www.biomedcentral.com/1472-6750/9/73
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Transduction of MPG-EGFP is dependent on an amiloride-sensitive endocytic pathway Figure 3
Transduction of MPG-EGFP is dependent on an amiloride-sensitive endocytic pathway. A. Flow cytometric analy-
sis of the MPG-EGFP uptake in the presence of various endocytosis inhibitors. The following concentrations were used: 10 μM 
cytochalasin D, 4 mM amiloride, and 5 mM MβCD. An inhibitor or DMSO (vehicle, 0.2%) was added to HeLa cells 30 min prior 
to the addition of MPG-EGFP, except for amiloride, which was added 10 min or 30 min prior to the addition of MPG-EGFP. 
MPG-EGFP at 40 μg/ml was treated to cells for 30 min in the presence of an inhibitor (see the diagram in B.). All cells were 
washed with the acid buffer before the analysis. Note the decreased MPG-EGFP signal in the amiloride-treated cells. MβCD 
treatment increased the intensity of EGFP signal significantly. These experiments were repeated at least three times with simi-
lar results and one representative set of data is shown. B. Confocal live images of HeLa cells treated with an endocytosis inhib-
itor as indicated. Photomicrographs were taken at 40X and zoomed in 2X. C. A barogram showing the averaged transduction 
efficiencies in the presence of various inhibitors. Errors bars represent the standard deviations. C, no protein added; EGFP, 40 
μg/ml EGFP protein; MPG-EGFP, 40 μg/ml MPG-EGFP; -, no drug added; D, 0.2% DMSO (vehicle); A10, 4 mM amiloride for 10 
min; A30, 4 mM amiloride for 30 min; C10, 10 μM cytochalasin D; M5, 5 mM MβCD.BMC Biotechnology 2009, 9:73 http://www.biomedcentral.com/1472-6750/9/73
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suggesting that the transduction of the MPG fusion pro-
tein utilizes unique pathway(s) which is amiloride-sensi-
tive and dynamin-dependent.
Blockade of a lysosomal pathway intensifies the 
accumulation of MPG-EGFP in endosomes
Chloroquine is an inhibitor which blocks the lysosomal
pathway of protein degradation [32]. We co-treated chlo-
roquine and MPG-EGFP to HeLa cells for 17 hr to exam-
ine if the blockade of the endolysosomal pathway leads to
the accumulation of the transduced MPG fusion protein.
As shown in Figure 6A, chloroquine-treated cells show
enlarged endosomes containing MPG-EGFP. Number of
MPG-EGFP-containing vesicles seems to have increased as
well. This observation was further explored by the vesicle
fractionation experiment. Prolonged treatment of MPG-
EGFP showed a lower band representing degradation
products. Chloroquine treatment increased the intensity
of MPG-EGFP band in the particulate fraction and, nota-
bly, the supernatant fraction in 100 μM chloroquine-
treated cells contains a much higher level of MPG-EGFP
than that in control cells. Collectively, the result shows
that the blockade of the lysosomal pathway would
increase the transduction efficiency and also lead to the
increased release of MPG fusion proteins into the cytosol
from the endosomes.
Uptake of MPG-EGFP in mouse eggs
CPP is an excellent tool for a short-term regulation of pro-
tein expression. As we showed herein, MPG fusion protein
may be a useful tool to deliver proteins to achieve short-
term regulation of protein expression. We tested if MPG
fusion protein can be used in mammalian eggs for this
purpose. So far, the transduction efficiency of any CPP-
fusion protein has not been tested in mammalian oocytes.
We obtained mouse eggs by the ovary puncture and
removed zona pellucidae with the acid Tyrode solution
(pH 2). Denuded eggs were treated with control EGFP or
MPG-EGFP recombinant protein at 40 μg/ml. As shown in
Figure 7, the treatment of EGFP did not give any fluores-
cence signal, while MPG-EGFP-treated eggs showed strong
signal around the ooplasmic periphery. As in the cultured
mammalian cells, 4 mM amiloride treatment disturbed
the uptake of MPG-EGFP, suggesting that similar endo-
cytic pathway is operative in the mouse egg. Whether
MPG fusion protein can be used to deliver proteins to eggs
without adverse effects requires further investigation.
Discussion
In a peptide form, MPG is highly effective in delivering
oligonucleotides, plasmid DNA, siRNAs, and peptides via
a non-covalent complex formation [12,15,33]. Unlike
other CPPs, the uptake of MPG-nucleic acid complex was
not inhibited by the treatment of cytochalasin B [34], and
this result suggests that the transduction of MPG peptide
is independent of macropinocytosis. CPP tag at the N-ter-
minal of a full-length protein would pose an entirely dif-
ferent conformation in the solution. Thus, we aimed to
investigate if a similar or distinct cellular pathway of trans-
duction is used for the uptake of the MPG-fusion protein.
The macropinocytosis is an actin-dependent endocytic
pathway which takes up solutes and fluid by the mem-
brane ruffling and fusion [23]. Several arginine-rich CPPs,
such as HIV TAT, Antp, Rev, and VP22 are shown to be
dependent on the lipid rafts-mediated macropinocytosis,
as their uptake is inhibited by cytochalasin D, MβCD, and
amiloride [9,10,35]. TAT-CRE, in a fusion protein form,
also used a similar endocytic pathway, and the release of
this fusion protein from macropinosomes can be
improved by the addition of TAT peptides conjugated
with the influenza virus hemagglutinin fusogenic motif
[10].
We found that, unlike TAT-fusion protein and arginine-
rich CPPs, MPG-EGFP is likely to use a specific endosomal
pathway which is sensitive only to amiloride among other
endocytosis inhibitors we used. Since the uptake of MPG-
EGFP is resistant to actin depolymerization, the macropi-
nocytosis is ruled out. Likewise, caveolae and cholesterol
both are not required for the transduction of MPG-EGFP,
suggesting that lipid rafts are not associated with the
uptake. Notably, the overexpression of the mutant form of
dynamin could partially reduce MPG-EGFP uptake in
HeLa cells, suggesting that the GTPase activity of
dynamins may be involved in the transduction. A recent
report showed that the transduction of VP22-EGFP fusion
protein was similarly dependent on dynamins, but the
uptake of VP22-EGFP is sensitive to MβCD and CytoD
[36]. Thus, the transduction pathway is seemingly dis-
tinct. Collectively, our results indicate that the transduc-
tion of MPG-EGFP seems to utilize a less well-
characterized endocytic pathway [23] and suggest that the
transduction of MPG-EGFP is dependent on more than
singular endocytic pathway, as amiloride and dynamin
mutant are both able to reduce the transduction effi-
ciency.
One unique feature of MPG-EGFP transduction is that the
sequestration of plasma membrane cholesterol increased
cytosolic labeling of this fusion protein (Figure 3). As the
cholesterol depletion has a negative effect on the trans-
duction of many CPPs including TAT-fusion protein, this
observation further supports that MPG-fusion protein uti-
lizes a distinct endocytic pathway. Enhanced labeling of a
fluorescence-tagged octaarginine peptide in the presence
of MβCD has been reported and it was suggested that the
entry of this peptide depends on more fluidic region of
the plasma membrane with less cholesterol [11]. Whether
this interpretation can be applied to the case of MPG-
fusion protein requires further investigation.BMC Biotechnology 2009, 9:73 http://www.biomedcentral.com/1472-6750/9/73
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The mechanisms of endocytosis are diverse and new infor-
mation is continuously being added. The amiloride-sensi-
tive pathway that MPG-EGFP depends on may be
somewhat associated with clathrin- and caveolin-inde-
pendent endocytosis. However, the mechanisms of this
pathway mostly remain unknown [37,38]. One novel
CPP, namely C105Y, has been reported to use a clathrin-
and caveolin-independent endocytosis [39]. The amilo-
ride-sensitive uptake of MPG-EGFP seems to be reminis-
cent of what was previously described as one type of the
endocytic uptake of Chlamydiae [40]. This intracellular
bacterium utilizes multiple endocytic pathways, one path-
way being the cytochalasin D-resistant and amiloride-sen-
sitive pathway. This is very similar to what we observed
herein with the MPG-fusion protein. No other informa-
tion regarding this pathway is available to delineate the
molecular characteristics. A recent report evaluating the
entry of the human papillomavirus type 16 showed that
this virus utilizes tetraspanin-enriched microdomains,
another example of clathrin- and caveolin-independent
endocytosis [41]. More elaborate follow-up to dissect the
endocytic pathway of MPG-EGFP could serve as a tool to
characterize this pathway.
The GTPase dynamin is involved in multiple forms of
endocytosis, including caveolae-mediated, clathrin-medi-
ated, and some clathrin- and caveolae-independent endo-
cytic pathway [23]. Therefore, our result showing a partial
reduction of MPG-EGFP transduction after the overex-
pression of the DynK44A mutant cannot pinpoint which
pathway is utilized by the transduction of this fusion pro-
tein. Since the intracellular localization of MPG-EGFP to
some extent overlaps with that of transferrin, clathrin-
mediated endocytosis may be involved. However, clear
dissection on the role for dynamins in CPP transduction
warrants further investigation. As in the case of MPG pep-
tide [16], whether the initial interaction of MPG-fusion
protein with the cell surface also utilizes negatively
charged glycosaminoglycans needs further work. Like-
wise, studies on the interaction of MPG-fusion protein
with lipid membrane will address if MPG-fusion protein
bears a similar affinity towards lipids as MPG peptide
[22].
We previously showed that MPG-EGFP is effectively trans-
duced into the human amnion-derived mesenchymal
stem cells [42]. This system may also be applicable to the
oocyte system as a short-term manipulation of protein
expression, as we show herein.
Conclusion
In this work, we show that MPG fusion protein utilizes an
endocytic pathway(s) which is amiloride-sensitive and
partially dynamin-dependent, which is entirely different
from other widely used CPPs. Thus, we suggest that the
MPG fusion protein could be further developed as a novel
tool of "protein therapeutics", with potentials to be used
in various cell systems including mammalian oocytes.
Furthermore, the MPG fusion protein system can be used
to target and deliver cargos to certain subcellular compart-
ments. And it also may be a useful tool to explore the
mechanism of previously uncharacterized type of endocy-
tosis.
Methods
Cell culture
AN3CA human uterine adenocarcinoma cells, HeLa,
293T, NIH3T3, and BV2 cells were purchased from Amer-
ican Type Culture Collection (Rockville, MD, USA) and
Transduction of MPG-EGFP is independent on caveolae but  may share a pathway with transferrin Figure 4
Transduction of MPG-EGFP is independent on caveo-
lae but may share a pathway with transferrin. A. Jurkat 
cells were treated with 40 μg/ml MPG-EGFP for 1 hr. Cells 
were processed for flow cytometry after the acid wash. In 
Jurkat cells which lack caveolae, the transduction of MPG-
EGFP still occurs. Confocal live image of MPG-EGFP-treated 
Jurkat cells is shown at 80X. B. Live confocal images showing 
partial co-localization of transferrin (red) and MPG-EGFP 
(green) in HeLa cells, generating a yellow fluorescence. 
Transferrin was added at 50 μg/ml for 30 min along with 40 
μg/ml MPG-EGFP. Pre-treatment of amiloride (4 mM for 30 
min) significantly reduced MPG-EGFP transduction while 
transferrin uptake proceeds.BMC Biotechnology 2009, 9:73 http://www.biomedcentral.com/1472-6750/9/73
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MPG-EGFP uptake partially depends on the GTPase activity of dynamins Figure 5
MPG-EGFP uptake partially depends on the GTPase activity of dynamins. A. A diagram depicting the experimental 
scheme of B. B. A mutant form of dynamin I which lacks the GTPase activity (DynK44A, 1 μg) was transfected into HeLa cells 
and MPG-EGFP was added at 40 μg/ml for 1 hr. Transferrin was added to cells as a marker of dynamin-dependent endocytic 
pathway. After washing, cells were fixed and subjected to the immunofluorescence staining with anti-dynamin I antibody. Con-
trol, control transfection of 1 μg pEGFP-N1 plasmid showing a high efficiency of transfection. Arrows indicate that transfected 
cells show normal transferrin localization. Dyn + transferrin, transferrin cannot enter DynK44A-expressing cells (shown in 
green), showing efficient blockade of clathrin-mediated endocytosis by overexpression of this mutant form. Dyn + MPG-EGFP, 
MPG-EGFP was added at 40 μg/ml for 1 hr to DynK44A-transfected cells. Note the reduced MPG-EGFP localization (arrow-
heads) in DynK44A-expressing cells (shown in red). Dyn + MPG-EGFP + amiloride, 30 min pre-treatment of amiloride effectively 
blocked overall MPG-EGFP uptake. Photomicrographs are shown at 80X.BMC Biotechnology 2009, 9:73 http://www.biomedcentral.com/1472-6750/9/73
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were cultured in DMEM supplemented with 10% FBS
(Invitrogen, Carlsbad, CA, USA). Jurkat cells were cultured
in RPMI 1640 supplemented with 10% FBS.
Expression and purification of CPP-EGFP fusion proteins
Full-length EGFP was amplified using pEGFP-N1 vector
(Invitrogen) as a template and cloned into XhoI and
BamH1 sites of the pET15b vector (Novagen, Madison,
WI, USA). Transportan, MPG1, MPG2, and KALA frag-
ments were amplified by Klenow reaction, and then
cloned into NdeI and XhoI site in pET15b-EGFP. Other
CPP sequences were included in the 5' primers, directly
amplified using pET15b-EGFP as a template, and cloned
into the pGEM-T-Easy vector (Promega, Madison, WI,
USA). After sequence verification, fusion constructs were
released and cloned into NdeI and BamHI sites of the
pET15b-EGFP. Primer information is available upon
request.
Purification of CPP-fused recombinant proteins were per-
formed as described previously [43]. An overnight culture
of 1 ml (BL21(DE3), Novagen) was added to 100 ml LB
medium containing 100 μg/ml of ampicillin and incu-
bated at 37°C and 200 rpm to an OD600 of 0.5. Protein
expression was induced by adding 1 ml of 100 mM IPTG
solution and the culture was incubated for 6 h at 25°C
and 200 rpm. The cells were harvested by centrifugation
(10 min, 4000 rpm, 4°C) and the supernatant was dis-
carded. The cell pellet was resuspended in 4 ml of the lysis
buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imida-
zole, pH 8.0), and lysozyme was added to 1 mg/ml. Incu-
bation on ice for 45 min was followed by a freeze-thaw
cycle at -20°C and room temperature. The viscous lysate
was passed several times through a sterile 20-gauge
syringe needle and centrifuged (10 min, 10,000 rpm,
4°C). The supernatant was separated from the cell debris.
MPG1, MPG2, Buforin 2 and SynB1 fusion proteins and
EGFP were yielded as soluble fractions and purified in a
native state. Ni-NTA agarose resin (1 ml, 50% w/v slurry,
Qiagen Inc., Valencia, CA) was added to the supernatant
and the mixture was shaken at 25°C for 1 h. The lysate-Ni-
NTA mixture was loaded on a Poly-Prep column (Bio-Rad,
Hercules, CA, USA), drained, and then washed once with
2 ml of the lysis buffer and three times with 4 ml of the
wash buffer (50 mM NaH2PO4, 300 mM NaCl, 20 mM
imidazole, pH 8.0). The proteins were eluted from the col-
umn with the elution buffer (50 mM NaH2PO4, 300 mM
NaCl, 250 mM imidazole, pH 8.0). The buffer of the pro-
tein solution was exchanged to 1 ml of PBS buffer using a
centrifugal device (Amicon Ultra-15, Millipore, Billerica,
MA, USA). Transportan, Transportan 10, KALA, and Pep-
1 fusion proteins were yielded as insoluble inclusion bod-
ies and purified under a denaturating condition. Ni-NTA
agarose resin (1 ml, 50% w/v slurry) was added to the cell
debris in 2 ml of 8 M urea solution and the mixture was
stirred at 25°C for 1 hr. The lysate-Ni-NTA mixture was
loaded on a Poly-Prep column (Bio-Rad), drained, and
then washed three times with 4 ml of the buffer C (100
mM NaH2PO4, 10 mM Tris-Cl, 8 M urea, pH 6.3) and two
times with 1 ml of the buffer D (100 mM NaH2PO4, 10
mM Tris-Cl, 8 M urea, pH 5.9). The proteins were eluted
from the column with the buffer E (100 mM NaH2PO4, 10
mM Tris-Cl, 8 M urea, pH 4.5). The protein solution was
50-fold diluted with the renaturation buffer (35 mM KCl,
2 mM MgCl2, 50 mM Tris-HCl, 1 mM DTT, pH 7.5) and
incubated at 4°C overnight. The diluted solution was con-
centrated and the buffer was exchanged to 1 ml of PBS
buffer using a centrifugal device.
Fluorescence microscopy
Cells were seeded onto a 12-well plate at the density of 1
× 105 a day before the experiment. Cells treated with CPP-
EGFP or control EGFP at indicated concentrations were
washed with HBSS (Invitrogen), with the acid wash buffer
(0.2 M glycine, 0.15 M NaCl, pH 3.0) for 30 sec [44], and
then with HBSS again. The cellular uptake of CPP-EGFP
was visualized in HBSS by Zeiss AxioVert200 inverted
microscope equipped with GFP and DAPI filters (Carl
Zeiss, Jena, Germany). In some experiments, live images
were obtained by using Olympus FV1000 spectral confo-
cal microscope (Olympus, Tokyo, Japan) equipped with a
warm plate. In these experiments, cells were seeded onto
a glass-bottom plate (SPL Lifesciences, Pocheon, Korea)
and stained with 5 μg/ml FM4-64 (Invitrogen) for 1 min.
To observe MPG-EGFP uptake at different time points,
MPG-EGFP-treated cells were fixed with 4% paraformal-
dehyde (PFA) in PBS at 1 min, 5 min, 15 min, and 30 min
after transduction, washed with PBS, and visualized in
HBSS under an inverted microscope. Transferrin-Alexa
Fluor 546 conjugate and LysoTracker Red DND-99® were
purchased from Invitrogen.
Vesicle fractionation
A vesicle-enriched fraction and a cytosolic fraction from
MPG-EGFP-treated cells were prepared as follows. HeLa
cells on a 100 mm culture dish were treated with 40 μg/ml
MPG-EGFP for 1 hr and washed with HBSS and the acid
wash buffer. The lysis buffer (10 mM Tris-Cl [pH 7.4], 320
mM sucrose, 150 mM NaCl, 1 mM EDTA) of 400 μl were
added. Cells were then homogenized with a Dounce
homogenizer gently and centrifuged at 1000 × g for 10
min at 4°C. The supernatant was then centrifuged at
100,000 × g for 1 hr at 4°C. The resultant supernatant is
the cytosolic fraction, and the pellet is the particulate frac-
tion containing vesicular structures within cells. These
samples were run on 10% SDS-PAGE gel, blotted onto a
nitrocellulose paper, and subjected to Western blottingBMC Biotechnology 2009, 9:73 http://www.biomedcentral.com/1472-6750/9/73
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using anti-GFP antibody (Young-In Frontier, Seoul,
Korea).
Inhibition of endocytosis
To block general endocytosis at 4°C, cells were plated
onto a 2-well slide chamber and precooled on ice for 20
min. All reagents were also precooled on ice. MPG-EGFP
at 40 μg/ml was added to the cells and incubated for 30
min on ice. After 30 min, cells were briefly fixed with 4%
PFA in PBS and slides were mounted using Profade Gold
antifade reagent (Invitrogen) to be visualized under an
inverted microscope. Chloroquine, cytochalasin D, ami-
loride, and methyl-β-cyclodextrin were purchased from
Sigma-Aldrich (St. Louis, MO, USA) and used at indicated
concentrations.
Flow Cytometric Analysis
MPG-EGFP-treated cells were washed with HBSS and the
acid wash buffer, and then trypsinized with 0.01%
trypsin-EDTA solution for 10 min. Cells were resuspended
in DMEM supplemented with 10% FBS, and washed with
PBS containing 3% FBS. After washing, cells were ana-
lyzed on FACSCalibur flow cytometer (BD Biosciences,
Franklin Lakes, NJ, USA) equipped with Cell Quest Pro
software (BD Biosciences).
Transfection of DynaminK44A
For transfection of dynamin-1 K44A mutant cDNA [27],
Fugene HD (Roche, Indianapolis, IN, USA) and 1 μg of
plasmid DNA were mixed in the serum-free media at 4:1
ratio and incubated for 15 min at RT. The mixture was
added to HeLa cells seeded in 2-well slide chambers.
Twenty-four hours later, 40 μg/ml MPG-EGFP was treated
to cells for 1 hr and processed for the immunofluores-
cence staining [42]. Transferrin at 50 μg/ml was added to
these cells for 30 min prior to the fixation. Cells were fixed
with 4% PFA, nonspecific antiserum binding was blocked
with 2% BSA/PBS for 60 min. Cells were incubated for 1
hr with anti-dynamin I mouse monoclonal antibody
diluted to 1:100 in 2% BSA/PBS. Following three washes
with 2% BSA/PBS, a goat anti-mouse secondary antibody
conjugated with Alexa 568 or Alex 488 (Invitrogen, 1:250
in 2% BSA/PBS) was applied for 30 min. Subsequently
slides were washed with 2% BSA/PBS and nuclei were
Chloroquine effectively blocks the endolysosomal pathway of  transduced MPG-EGFP Figure 6
Chloroquine effectively blocks the endolysosomal 
pathway of transduced MPG-EGFP. A. 100 μM chloro-
quine was added along with 40 μg/ml MPG-EGFP for 17 hr. 
Note the increased intensity of MPG-EGFP signal and 
enlarged vesicle. Confocal live images are shown at 80X. B. 
Vesicle fractionation was performed using HeLa cells treated 
with MPG-EGFP and chloroquine for 17 hr. Note that the 
vesicular uptake of MPG-EGFP intensified in the presence of 
chloroquine, and that the cytosolic fraction also contains a 
significant amount of MPG-EGFP. EGFP, 40 μg/ml EGFP; 
MPG-EGFP, 40 μg/ml MPG-EGFP; Chl 50, MPG-EGFP plus 50 
μM chloroquine; Chl 100, MPG-EGFP plus 100 μM chloro-
quine; S, supernatant containing the cytosolic fraction; P, pel-
let containing the intracellular vesicles. The asterisk indicates 
that the band is a merged doublet due to the prolonged 
exposure, and the arrow points the expected size of MPG-
EGFP. Western blotting was performed with anti-GFP anti-
body.
Successful transduction of MPG-EGFP into the mouse  oocytes Figure 7
Successful transduction of MPG-EGFP into the 
mouse oocytes. Mature oocytes were obtained from 4-
week mouse ovaries, and zona pellucidae were removed by 
the acid Tyrode solution. EGFP or MPG-EGFP was added to 
M16 media for 1 hr. Note the strong peripheral EGFP signal 
in MPG-EGFP treated oocytes. Amiloride, as in HeLa cells, 
effectively blocked the transduction of MPG-EGFP.BMC Biotechnology 2009, 9:73 http://www.biomedcentral.com/1472-6750/9/73
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stained with TO-PRO-3-iodide (Invitrogen, 1:500) for 20
min. After a final wash with PBS, coverslips were mounted
using ProLong Gold antifade reagent (Invitrogen). Speci-
mens were examined by using Olympus Fluoview™
FV1000 confocal microscope (Olympus, Japan) and ana-
lyzed using the software Fluoview version 1.5, a platform
associated with the confocal microscope. The primary
antibody used is specific for the neuron-specific dynamin-
1 (BD Biosciences, San Jose, CA, USA) as the epitope at the
C-terminal region is variable in Dynamin-2 [30].
Confocal laser scanning microscopy
Cells were split and seeded on the poly-L-lysine coated
cover slips placed in a 6-well plate a day before the exper-
iment. Cells were treated with CPP-EGFP or EGFP for one
hour and intracellular localization of EGFP was observed
as follows. Cells were washed twice with PBS and fixed for
10 min in 4% PFA in PBS. Cells were washed with PBS
three times, counterstained with TO-PRO-3-iodide in PBS
(1:500, Invitrogen) for 20 min, and rinsed three times in
PBS. Coverslips were mounted onto sections with Pro-
Long Gold mounting media (Invitrogen) and sealed with
nail polish. Images were obtained using the Olympus
Fluoview™ FV1000 confocal microscope. For live imaging,
unfixed cells on a glass-bottom plate were placed onto a
warm plate and images were obtained for 10–20 min at
20 sec interval.
Oocyte handling
Five-week old virgin CD-1 female mice were purchased
from Orient-Bio (Gyunggi-do, Korea). Mice were main-
tained in accordance with the policies of the Institutional
Animal Care and Use Committee in Konkuk University.
Female mice were injected i.p. with 5 I.U. pregnant mare's
serum gonadotropin (PMSG) (Sigma) to stimulate the
growth of preovulatory follicles. Forty-eight hrs later, ova-
ries were taken from these mice and were punctured with
fine forceps to release fully grown oocytes. Cumulus cells
were removed by repeated pipetting and zona pellucidae
were digested with the acid Tyrode solution [45]. Purified
EGFP or MPG-EGFP in M16 media was added to the
denuded oocytes at the indicated concentration and EGFP
signal was visualized under an inverted fluorescence
microscope.
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